Allergan announced recently that it received an additional approval from Health Canada for FIBRISTAL® (ulipristal acetate, 5 mg) for the intermittent treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age. Each treatment course is three months, given in repeated courses.
Bayer Pharmaceuticals continues it's phase III study, ASTEROID, which evaluates Vilaprisan in women suffering from uterine fibroids. This 2mg Uliprital Acetate tablet is part of a trial that aims for a new symptom control for symptomatic uterine fibroids in a long-term treatment option.
According to the article, despite its less invasive nature, UFE has yet to be fully embraced in the medical community as a fertility-preserving treatment for women with fibroids due to concerns that the procedure may cause inadequate blood flow to the endometrium, or lining of the uterus, and the ovaries.
Member since 2014
Founder, 2012
Member since 2012
Member since 2016
Member since 2014
Member since 2017
Out of every 100 women over 40, 25 experience Fibroids symptoms.
Appx. 25,000 hospital visits annually are Fibroids related.
